Canada HIV Drugs Market Analysis Report 2022 to 2030

Canada HIV Drugs Market Analysis

$ 3999

Canada HIV Drugs Market is at around $2.54 Bn in 2023 and is projected to reach $3.25 Bn in 2030, exhibiting a CAGR of 3.6% during the forecast period. The market is growing due to the prevalence of HIV/ AIDS, government initiatives and funding, and advancements in drug therapies. The market is dominated by key players like ViiV Healthcare, Gilead Sciences, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffman-La Roche Ltd., Cipla, Teva Pharmaceutical Industries Ltd., and Johnson & Johnson.

ID: IN10CAPH011 CATEGORY: Pharmaceuticals GEOGRAPHY: Canada AUTHOR: Aneri Parekh

Buy Now

Canada HIV Drugs Market Executive Summary

Canada HIV Drugs Market is at around $2.54 Bn in 2023 and is projected to reach $3.25 Bn in 2030, exhibiting a CAGR of 3.6% during the forecast period.

The Canadian HIV Drugs Market includes a range of antiretroviral medications, such as combination therapies and more recent, cutting-edge treatments, that are intended to inhibit the spread of HIV/ AIDS, boost immunity, and improve the quality of life for those who are infected. The dynamics of this industry in the Canadian context are significantly shaped by elements including access to medication, medical research developments, healthcare infrastructure, and governmental legislation.

The market for HIV medications in Canada is expanding gradually, propelled by rising levels of awareness, diagnosis, and treatment initiatives. Leading companies in the field are concentrating on creating novel treatments that have higher efficacy and fewer negative effects. The goal of national healthcare initiatives and programs is to increase HIV patients' access to care and assistance.

The global HIV drug market has expanded dramatically, with a value predicted at $31.7 Bn in 2023. Rising HIV diagnosis rates and government efforts to improve awareness about HIV management have had a favorable impact on the HIV drug sector. The market landscape is changing due to growing generic competition. The path forward is dependent on eliminating affordability barriers, combating stigma, and increasing access to treatment in developing nations.

ViiV Healthcare is the market leader in Canadian HIV medications, accounting for around 25% of the total. In Canada, the firm offers 16 prescription drugs, including two-drug regimens and long-acting HIV therapy. The company's main products in Canada include Cabenuva (long-acting injectable), Triumeq (single-tablet regimen), Tivicay (dolutegravir), Epivir (lamivudine), and Atripla. ViiV Healthcare invests extensively in R&D, with a pipeline of innovative HIV therapies in development.

Canada HIV drugs market

Market Dynamics

Market Growth Drivers:

HIV/ AIDS prevalence: The number of people in Canada living with HIV/ AIDS is a major factor in the need for HIV medications. 1,833 new cases of HIV were diagnosed in 2022, a 24.9% rise from 2021.

Government Funding and Initiatives: HIV medicine sales are rising as a result of government campaigns and programs to combat HIV/ AIDS. The funding of prevention, treatment, and research projects guarantees a consistent supply and availability of HIV drugs.

Developments in Drug Therapies: New antiretroviral drugs and drug delivery systems are among the HIV drug therapies that are driving the market's expansion.

Market Restraints:

Regulatory Environment: Strict regulatory criteria for drug approval and price can have an impact on the availability and affordability of HIV medications in Canada.

Comorbidities and Coinfections: The prevalence of comorbidities or coinfections among HIV patients might influence treatment decisions and drug regimen selection, hence affecting market demand for specific pharmaceuticals.

Supply Chain Challenges: Pharmaceutical supply chain disruptions, whether caused by production concerns, transportation delays, or other circumstances, can have an influence on drug availability and distribution in Canada.

Notable Recent Updates

January 2024, US Food and Drug Administration approved a Florida plan to import pharmaceuticals from Canada. Residents of the US can now pay for their purchases at Canadian pharmacies

Healthcare Policies and Regulatory Landscape

Health Canada's HPFB (Health Products and Food Branch) is the national agency in charge of overseeing and evaluating the efficacy, safety, and quality of therapeutic and diagnostic goods made available to Canadians. The drug product is subjected to a health technology assessment, following which a recommendation is issued regarding its eligibility for public funding. A pricing discussion happens when a health technology assessment gives a product a positive recommendation. Health Canada applies strict scientific standards that necessitate comprehensive assessments of potential risks and benefits as well as reliable clinical data. Producers may find this expensive and time-consuming, particularly when producing unique or specialized drugs.

Competitive Landscape

Key Players:

ViiV Healthcare
Gilead Sciences
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals
Merck & Co.
Bristol-Myers Squibb
AbbVie Inc.
F. Hoffman-La Roche Ltd.
Cipla
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Drugs Market Segmentation

By Drug Class

Integrase Inhibitors
Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Combination HIV Medicines
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.